Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival.

Ann Med · 2023 · PMC10243386 · PMID 37272300

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a phase II trial of pembrolizumab for recurrent ovarian cancer, OCCC showed a trend of higher response rate than other subtypes [ 32 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.